大盘午后全线翻绿，四连阳不断创新高的港股创新药精选ETF（520690）下跌2%，换手率达到19.16%。 得益于港股通+ ETF场内交易的双重优势，港股创新药精选ETF（520690）自8月1日上市以来净流入额5850万元，最新规模增长至4.04亿元，支持T+0交易，一键实现A股账户对港股创新药主题的便捷配置。 港股创新药精选ETF跟踪恒生港股通创新药精选指数，聚焦港股创新药龙头与高研发属性标的，适合进攻性获取创新药板块β。值得一提的是，恒生港股通创新药精选指数将在9月迎来指数编制调整，剔除CXO企业，调整后指数的创新药指数的“纯度”将变为百分百，更聚焦于创新药研发核心环节。 今年以来，港股创新药强势上涨，港股创新药精选ETF标的指数年内涨幅107%，最新PE(TTM)为30.87倍，位于近十年33.03%的历史分位，估值处于历史低位。 业内认为，考虑到创新药密集兑现期到来，国家政策支持力度持续明确，创新药产业发展趋势及产业升级主线已经较明确。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.